InflaRx is a specialized biopharmaceutical company advancing targeted therapies designed to suppress inflammation by selectively inhibiting the immune system's C5a/C5aR signaling pathway—often implicated in life-threatening and chronic inflammatory conditions. Their platform centers on pioneering anti-C5a and C5aR agents engineered to precisely reduce harmful inflammation while preserving essential immune functions. Based in Jena, Germany, with additional facilities in Munich and Ann Arbor, Michigan, InflaRx’s scientific mission is rooted in delivering transformative treatments for patients facing high unmet medical needs.